奥克萨利普拉丁/诺坎塔里丁原药共载纳米颗粒:协同DNA修复阻断加PD-L1下调抑制瘤生长和转移
Peng-Wei Chen1,2, Yu-Meng Zhang1,2, Lin-Song Li1,2
1Henan Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, China.
Advanced healthcare materials
|February 20, 2026
概括
这项研究引入了IROTD纳米颗粒,将光疗与氧化 (OXA) 和诺坎塔里丁 (NCTD) 结合起来,触发免疫细胞死亡 (ICD) 并增强抗瘤免疫力,以有效治疗癌症.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症免疫疗法癌症免疫疗法
背景情况:
- 光疗与氧沙 (OXA) 结合的疗法在触发免疫细胞死亡 (ICD) 和抗瘤免疫力方面表现有前途.
- 开发有效的纳米平台对于向癌症治疗至关重要.
研究的目的:
- 构建IROTD纳米粒子 (IROTDNP) 用于联合化疗-免疫疗法.
- 研究IROTDNP在诱导ICD,抑制瘤生长和激活全身抗瘤免疫力的有效性.
主要方法:
- 诺坎塔里丁 (NCTD) -OXA结合聚合物 (P2) 与DTIR780光敏感剂的自组装,以形成IROTD NP.
- 尼尔射线激光照射 (808nm) 激活IROTDNP,诱导热量,活性氧物种 (ROS) 和药物释放 (OXA和NCTD).
- 在体外和体内评估DNA损伤,ICD诱导,PD-L1表达,T细胞透和瘤生长抑制.
主要成果:
- IROTD NPs有效地产生热量,ROS,并在NIR照射时释放治疗剂,导致严重的DNA损伤和ICD.
- NCTD成分抑制了DNA修复和降低PD-L1的调节,增强了细胞毒性T细胞透和全身抗瘤免疫力.
- IROTDNP通过EPR效应在瘤部位积累,显著抑制初级和远程瘤生长,并促进CD4+/CD8+T细胞的招募.
结论:
- IROTD NPs代表了一个合理设计的纳米平台,用于组合化疗-免疫疗法.
- 这种策略有效地触发了全身免疫反应,为癌症治疗提供了前性的方法.
- 开发的纳米平台显示了治疗原发性和转移性瘤的巨大潜力.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.2K
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
6.6K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
663
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
663
Site-Targeted Drug Delivery Systems: Polymeric Carriers
34
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
34
